VRTX: Vertex Pharmaceuticals

_Last updated 2026-10-30 12:00 ET from report. Screening/research, not investment advice._

Business

Cystic fibrosis franchise (Trikafta/Kaftrio, Alyftrek), Casgevy (with CRISPR Therapeutics), Journavx (non-opioid acute pain). TRAI sector: Healthcare. Top 60d ρ: AMGN 0.65, PFE 0.63, LLY 0.63, JNJ 0.63, GILD 0.56.

Catalysts, guidance & news

• Q3 2026: Mon 2026-11-02 AMC, call 4:30 PM ET (Vertex newsroom). Consensus $3.40B / $4.92, Trikafta est. $2.49B (Zacks via Yahoo, 2026-10-27); drillr cites $4.76 EPS as of 10-16.
• FY26 guide $13.1–13.2B (raised 08-03), consensus $13.247B (drillr). Q2 Journavx $50M (+71% q/q) (Vertex IR).
• Povetacicept (IgAN) FDA decision expected 2026-11-30 (Zacks).
• 2026-10-30: +3.44% at 12:02 ET with the defensive pharma bid.

TRAI data

• Last 4 prints: avg |gap| 0.95% (0.43 ATR), gap fill 75% (TRAI /api/events).

Report links

• 2026-10-30 12:00 — Monday AMC prints

2026-11-02 14:00 update

• Consensus $4.76 / $3.41B (Investing.com) to $4.82 / $3.42B (MarketBeat); first quarter with Crinetics (closed 09-01) and a promised 2026 guidance update; Alyftrek modelled ~$688M; povetacicept PDUFA 11-30 (Investing.com, 2026-11-02). Missed EPS by $0.01 last quarter.
• 2026-11-02 14:00 report

2026-11-02 16:00 update

• Q3 (accepted 16:05:46 ET): rev $3.44B vs $3.40–3.42B; non-GAAP EPS $4.76 vs $4.76–4.92; ALYFTREK $705.8M; FY rev guide $13.15–13.25B (raised), non-GAAP opex ~$6.0B (raised from $5.65–5.75B) (SEC ex-99.1).
• First AH print +4.6% on ~7k shares was noise: −0.4% at 16:16, −1.1% at 16:32. Link to REGN (LM) ρ 0.61: no gap-risk flag.
• Report

2026-11-02 17:00 update

• AH +1.24% at 17:05 ET (560.00). Release-verified guide: FY rev $13.15–13.25B (from $13.1–13.2B), non-GAAP combined opex ~$6.0B (from $5.65–5.75B), PALSONIFY $40–50M (SEC ex-99.1). REGN (sole LM) ρ 0.61: below the 0.7 tag bar.
• Report

2026-11-06 15:00 update — cluster-5 soft green after milder Thu crush

• Thu −1.19% (milder than peers); Fri ~15:09 ~546.94 / ~+0.82%. SM Healthcare ×5 residual (suspended). Cluster 5; VRTX–LLY 0.65, GILD–VRTX 0.68; REGN–VRTX 0.45 (singleton peer).
• No verified Thu company-specific catalyst. Feeds S-149. Next print null on upcoming (last was 11-02 AMC).
• Source: 2026-11-06 15:00 healthcare split.